EUHASS: The European Haemophilia Safety Surveillance system
作者： M. Makris , G. Calizzani , K. Fischer , E.A. Gilman , C.R.M. Hay
DOI: 10.1016/S0049-3848(10)70150-X
关键词:
摘要: Pharmacovigilance is an essential element of any drug treatment and considering the history adverse events due to products used treat inherited bleeding disorders, it should be integral component modern haemophilia treatment. Because disorders are rare, a multicentre, preferably multinational, event reporting scheme for all clotting factor required. EUHASS European, prospective, multicentre in field disorders.
elsevier.com
sci-hub.se 参考文章(5)
M. WEINSTEIN, M. MAKRIS, C.A. LUDLAM, Biovigilance and pharmacovigilance for haemophilia Haemophilia. ,vol. 16, pp. 17- 21 ,(2010) , 10.1111/J.1365-2516.2010.02288.X
R. LASSILA, E. ARMSTRONG, Current challenges of pharmacovigilance in bleeding disorders: converting the burden to benefit. Haemophilia. ,vol. 16, pp. 231- 237 ,(2010) , 10.1111/J.1365-2516.2009.02102.X
Pier Mannuccio Mannucci, Stefano Duga, Flora Peyvandi, Recessively inherited coagulation disorders Blood. ,vol. 104, pp. 1243- 1252 ,(2004) , 10.1182/BLOOD-2004-02-0595
C. M. MILLAR, N. CONNOR, G. DOLAN, C. A. LEE, M. MAKRIS, J. WILDE, M. WINTER, J. W. IRONSIDE, N. GILL, F. G. H. HILL, Risk reduction strategies for variant Creutzfeldt-Jakob disease transmission by UK plasma products and their impact on patients with inherited bleeding disorders Haemophilia. ,vol. 16, pp. 305- 315 ,(2010) , 10.1111/J.1365-2516.2010.02220.X
Frits Rosendaal, Louis Aledort, Jeanne Lusher, Chantal Rothschild, Jørgen Ingerslev, Gilbert White, Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thrombosis and Haemostasis. ,vol. 85, pp. 560- 560 ,(2001) , 10.1055/S-0037-1615621